How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals
AffiliationMédecins Sans Frontières, Campaign for Access to Essential Medecins, Geneva, Switzerland; Médecins Sans Frontières, Khayelitsha, South Africa; Geneva Teaching Hospital, Geneva, Switzerland
MetadataShow full item record
JournalDrug Discovery Today
AbstractClinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.
- Antiretroviral therapy in the developing world.
- Authors: Chulamokha L, DeSimone JA, Pomerantz RJ
- Issue date: 2005
- Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
- Authors: Dickinson L, Khoo S, Back D
- Issue date: 2010 Jan
- Emerging antiretroviral drug interactions.
- Authors: Pham PA, Flexner C
- Issue date: 2011 Feb
- Emerging resistance profiles of newly approved antiretroviral drugs.
- Authors: Daar ES
- Issue date: 2008 Oct-Nov
- [CCR5 antagonists: a new class of antiretrovirals].
- Authors: Peytavin G, Calvez V, Katlama C
- Issue date: 2009 Jan-Feb